Differential effects of direct oral anticoagulants on experimental diabetic kidney disease
Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S12
DOI: 10.1055/s-0044-1785253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Khurrum Shahzad und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Diabetic kidney disease (DKD) is the main cause of end-stage renal disease worldwide. The underlying mechanism remains incompletely defined, but dysregulated coagulation activity has been closely linked to DKD. Direct oral anticoagulants (DOACs) inhibit specific coagulation factors and may hence differentially affect the hemostatic system. Here we studied the effects of DOACs targeting coagulation factor, fXa or fIIa in experimental DKD.
Methods
The effect of DOACs was studied in murine models of DKD (streptozotocin-induced type 1 diabetes model). Mice were treated with a direct fIIa inhibitor (fIIai) or direct fXa inhibitor (fXai) for 14 weeks. We assessed albuminuria, glomerular and renal injury, expression of p21 and senescence markers (immunoblotting, immunoflourescent staining), as well as eicosanoids (including resolvins) and inflammatory markers in the blood. Lastly, fXai effect on DKD was studied in diabetic mice treated with resolvin D2 receptor inhibitor.
Results
Kidney damage, as reflected by albuminuria, glomerular mesangial expansion, glomerular basement membrane thickness, renal fibrosis and premature senescence was strongly reduced in diabetic mice treated with fXai. In contrast, diabetic mice treated with fIIai showed only partial protection. Plasma levels of resolvin D2 (pro-resolving eicosanoid) was higher in fXai treated mice compared to fIIai. Inhibition of the resolvin D2 receptor abolished the nephroptotective effect associated with fXai.
Conclusion
These data establish that targeted interventions of specific coagulation proteases using DOACs differentially modulates experimental DKD. fXai provided superior protection against DKD by promoting resolvin D2 signaling. These data imply that in the case of anticoagulant therapy in patients with DKD, inhibitors targeting fXa may be superior. Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Shahzad, K., Fatima, S., Farhan, M. A., Ambreen, S., Khawaja, H., Kohli, S., & Isermann, B. (2024). Differential effects of direct oral anticoagulants on experimental diabetic kidney disease. Diabetologie und Stoffwechsel, 19(S 01 S 01), S12. https://doi.org/10.1055/s-0044-1785253
Vancouver
Shahzad K, Fatima S, Farhan MA, Ambreen S, Khawaja H, Kohli S, et al. Differential effects of direct oral anticoagulants on experimental diabetic kidney disease. Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S12. doi:10.1055/s-0044-1785253
BibTeX
@article{Shahzad2024,
author = {Shahzad, Khurrum and Fatima, Sameen and Farhan, Muhammad Asad and Ambreen, Saira and Khawaja, Hamzah and Kohli, Shrey and Isermann, Berend},
title = {Differential effects of direct oral anticoagulants on experimental diabetic kidney disease},
journal = {Diabetologie und Stoffwechsel},
year = {2024},
volume = {19},
number = {S 01 S 01},
pages = {S12},
doi = {10.1055/s-0044-1785253}
}
EUVIMED